FDA extends VTAMA sNDA review for atopic dermatitis to March 12, 2025

Organon & Co.

FDA extended target action date by 3 months to March 12, 2025; original date was December 12, 2024.
FDA requested final datasets and clinical study report from long-term extension study, deemed a major amendment.
No concerns raised regarding safety, efficacy, or approvability of VTAMA for atopic dermatitis.
Organon expects VTAMA full-year 2025 revenue of ~$125M; impact of ~75 bps headwind to Adjusted EBITDA margin.
Updated guidance provided as a supplement to prior Q3 2024 earnings call commentary.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.